Microbot Medical (NASDAQ: MBOT) spotlights LIBERTY at SIO 2026

Rhea-AI Filing Summary

Microbot Medical Inc. filed a report stating that it is attending the Society of Interventional Oncology annual meeting in Savannah, Georgia, held February 4–8, 2026. The timing coincides with the company’s limited market release of its LIBERTY Endovascular Robotic System.

During the meeting, Microbot plans to share practical insights and personal experiences from physicians who have used LIBERTY across different hospitals and procedure types. The company furnished, but did not file, a related press release as Exhibit 99.1 under Regulation FD.

false 0000883975 0000883975 2026-02-05 2026-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On February 5, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company’s limited market release of the LIBERTY Endovascular Robotic System, will allow the Company to share practical insights and personal experiences from physicians who have used LIBERTY across hospitals and procedure types.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: February 5, 2026

FAQ

What did Microbot Medical Inc. (MBOT) disclose in its latest 8-K filing?

Microbot Medical disclosed that it is attending the Society of Interventional Oncology annual meeting in Savannah, Georgia, February 4–8, 2026, during the limited market release of its LIBERTY Endovascular Robotic System, and furnished a related press release as Exhibit 99.1 under Regulation FD.

What is the significance of the SIO annual meeting for Microbot Medical (MBOT)?

The SIO annual meeting aligns with Microbot Medical’s limited market release of its LIBERTY Endovascular Robotic System, giving the company a venue to share practical insights and personal experiences from physicians who have used LIBERTY in different hospitals and procedure types.

What information did Microbot Medical provide about the LIBERTY Endovascular Robotic System?

Microbot Medical stated that the SIO conference occurs during the limited market release of its LIBERTY Endovascular Robotic System and that it plans to present practical insights and personal experiences from physicians who have already used LIBERTY in various hospital settings and procedure types.

How is the Microbot Medical (MBOT) press release treated under securities laws?

Microbot Medical indicated that the press release attached as Exhibit 99.1 is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, limiting its exposure to certain statutory liabilities associated with filed information.

What exhibits were included with Microbot Medical’s February 5, 2026 8-K?

The 8-K includes Exhibit 99.1, which is a press release about Microbot Medical’s participation in the SIO annual meeting, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document, satisfying technical disclosure requirements.

Does Microbot Medical’s 8-K indicate any determination of materiality for the disclosed information?

Microbot Medical explicitly states that the report will not be deemed an admission as to the materiality of any information in Item 7.01 or Exhibit 99.1, clarifying that inclusion of the disclosure does not concede its material significance under securities law standards.